StreetInsider.com News Articles

Hercules Capital Inc (HTGC) PT Lowered to $15 at UBS

Fri, 13 Mar 2026 09:09:52 -0400

UBS analyst Vilas Abraham lowered the price target on Hercules Capital Inc (NYSE: HTGC) to $15.00 (from $19.50) while maintaining a Neutral rating.

Form 4 Hercules Capital, Inc. For: Mar 05 Filed by: Meyer Seth H

Mon, 09 Mar 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260309/26131840.html

Form 4 Hercules Capital, Inc. For: Mar 05 Filed by: Meyer Seth H

Mon, 09 Mar 2026 16:00:00 -0400

si-local-file:///var/storage/secattach/20260309/26131840.html

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

BOSTON & MONTREAL--(BUSINESS WIRE)-- enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the first

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

enGene Reports First Quarter 2026 Financial Results and Provides Business Update

Mon, 09 Mar 2026 07:00:00 -0400

LEGEND pivotal cohort update planned for a spring 2026 medical conference

12-month complete response data from LEGEND pivotal cohort expected in 2H 2026

Biologics License Application (BLA) submission for detalimogene planned for 2H 2026

Cash and marketable securities of $312.5 million expected to provide cash runway into 2H 2028

Expanded $125 million debt facility with Hercules Capital provides additional financial flexibility to advance detalimogene development and commercialization for bladder cancer

Form 4/A Hercules Capital, Inc. For: Mar 04 Filed by: Follmann Christian

Thu, 05 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260305/26120375.html

Form 4/A Hercules Capital, Inc. For: Mar 04 Filed by: Follmann Christian

Thu, 05 Mar 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260305/26120375.html

Form 4 Hercules Capital, Inc. For: Mar 04 Filed by: Follmann Christian

Thu, 05 Mar 2026 15:53:00 -0400

si-local-file:///var/storage/secattach/20260305/26118524.html

Form 4 Hercules Capital, Inc. For: Mar 04 Filed by: Follmann Christian

Thu, 05 Mar 2026 15:53:00 -0400

si-local-file:///var/storage/secattach/20260305/26118524.html

Form 4 Hercules Capital, Inc. For: Mar 04 Filed by: Randhawa Paramjeet K

Thu, 05 Mar 2026 14:55:00 -0400

si-local-file:///var/storage/secattach/20260305/26118252.html

Form 4 Hercules Capital, Inc. For: Mar 04 Filed by: Randhawa Paramjeet K

Thu, 05 Mar 2026 14:55:00 -0400

si-local-file:///var/storage/secattach/20260305/26118252.html